New hope for tough cancers: experimental drug LP-284 enters human testing

NCT ID NCT06132503

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called LP-284 in about 110 adults whose lymphomas or solid tumors have returned or stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the body and whether it can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma lymphoma neoplasm Recurrence refractory malignant neoplasm sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • START Mountain Region

    RECRUITING

    West Valley City, Utah, 84119, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact